1128268-02-9

Basic information

• Product Name: 1H-Pyrazole-4-carboxylic acid, 1-[6-(2-hydroxyphenyl)-2-pyridinyl]-5-(trifluoromethyl)-, ethyl ester
• Synonyms: ethyl 1-(diphenylamino)-4,5-dioxo-2-phenyl-4,5-dihydro-1H-pyrrole-3-carboxylate
• CAS NO: 1128268-02-9
• Molecular Formula: C₂₅H₂₀N₂O₄
• Molecular Weight: 377.323
• Mol File: 1128268-02-9.mol

Chemical Properties

• Boiling Point: 565.1 °C at 760 mmHg
• Flash Point: 295.6 °C
• Density: 1.328 g/cm³
• CAS DataBase Reference: 1H-Pyrazole-4-carboxylic acid, 1-[6-(2-hydroxyphenyl)-2-pyridinyl]-5-(trifluoromethyl)-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazole-4-carboxylic acid, 1-[6-(2-hydroxyphenyl)-2-pyridinyl]-5-(trifluoromethyl)-, ethyl ester(1128268-02-9)
• EPA Substance Registry System: 1H-Pyrazole-4-carboxylic acid, 1-[6-(2-hydroxyphenyl)-2-pyridinyl]-5-(trifluoromethyl)-, ethyl ester(1128268-02-9)

Safety Data

• Hazardous Substances Data: 1128268-02-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1H-Pyrazole-4-carboxylic acid, 1-[6-(2-hydroxyphenyl)-2-pyridinyl]-5-(trifluoromethyl)-, ethyl ester is used as a potential pharmaceutical agent for its possible biological activity, which can be harnessed to develop new drugs targeting various diseases and conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 1H-Pyrazole-4-carboxylic acid, 1-[6-(2-hydroxyphenyl)-2-pyridinyl]-5-(trifluoromethyl)-, ethyl ester is used as a candidate for the development of new agrochemicals, potentially offering novel modes of action for pest and disease control in agriculture.
Used in Drug Design and Development:
1H-Pyrazole-4-carboxylic acid, 1-[6-(2-hydroxyphenyl)-2-pyridinyl]-5-(trifluoromethyl)-, ethyl ester is utilized in drug design and development processes due to its unique physicochemical properties, such as increased lipophilicity and metabolic stability, which can improve the pharmacokinetics and pharmacodynamics of new drug candidates.

Upstream product

• 1128268-00-7 ethyl 1-(6-chloropyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate 
• 269409-97-4 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol 
• 89466-08-0 2-hydroxyphenyl boronic acid 
• 571-55-1 ethyl 2-(ethoxymethylidene)-4,4,4-trifluoro-3-oxobutanoate 

Downstream Products

• 1128268-07-4 Ethyl 1-(6-{2-[(4-bromobenzyl)oxy]phenyl}pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate 
• 1160431-48-0 ethyl 1-{6-[2-(2-propen-1-yloxy)phenyl]pyridin-2-yl}-5-(trifluoromethyl)-pyrazole-4-carboxylate 
• 1128268-09-6 Ethyl 5-(trifluoromethyl)-1-[6-(2-{[4'-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)pyridin-2-yl]-1H-pyrazole-4-carboxylate 
• 1160433-13-5 ethyl 1-[6-(2-(4-(4-methoxyphenyl)benzyloxy)-phenyl)pyridin-2-yl]-5-trifluoromethyl-pyrazole-4-carboxylate 
• 1128268-04-1 Ethyl 1-[6-(2-{[4-(2-phenylethyl)benzyl]oxy}phenyl)pyridin-2-yl]-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate 
• 1160431-51-5 ethyl 1-(6-(2-(4-cyanobenzyloxy)-phenyl)pyridin-2-yl)-5-trifluoromethyl-pyrazole-4-carboxylate 
• 1160433-18-0 ethyl 1-[6-(2-(4-(4-cyanophenoxy)benzyloxy)-phenyl)pyridin-2-yl]-5-trifluoromethyl-pyrazole-4-carboxylate 
• 1305197-94-7 C₁₉H₁₃F₆N₃O₅S 
• 1128268-19-8 Ethyl 1-[6-(2-{[4-(hydroxymethyl)benzyl]oxy}phenyl)pyridin-2-yl]-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate 
• 1305170-07-3 C₃₂H₂₃F₆N₃O₄ 
• 1128268-37-0 ethyl 1-[6-(5-chloro-2-hydroxyphenyl)pyridin-2-yl]-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate 
• 1128268-77-8 ethyl 1-[6-(2-hydroxy-3-iodophenyl)pyridin-2-yl]-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate 
• 1128268-47-2 Ethyl 1-[6-(2-{[4-(1,4-dioxaspiro[4.5]dec-8-yl)benzyl]oxy}phenyl)pyridin-2-yl]-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate 
• 1240969-39-4 tert-Butyl 4-(4-((2-(6-(4-(ethoxycarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)phenoxy)methyl)phenyl)piperidine-1-carboxylate 

Relevant articles and documents

SOLUBLE GUANYLATE CYCLASE ACTIVATORS

This inventions relates to compounds having the structure Formula I and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.

Soluble Guanylate Cyclase Activators

This inventions relates to compounds having the structure Formula I and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.

2,6-DISUBSTITUTED PYRIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS

Disclosed are compounds of formula (I) wherein R1 and R2 are independently selected from hydrogen, halo, CF3, C1-4alkyl and allyl; Y represents (II), (III), (IV) or (V) wherein R3 represents CF3 or C1-4alkyl; and R3a represents CF3 or C1-4alkyl.

SOLUBLE GUANYLATE CYCLASE ACTIVATORS

A compound having the structure useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, angina pectoris, thromboses, restenoses, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver in a human or animal patient.